Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Condition: Pulmonary Tuberculosis Interventions: Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Drug: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Drug: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) Sponsors: Bill & Melinda Gates Medical Research Institute; Global Alliance for TB Drug Development; Janssen Pharmaceutica; Otsuka Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials